Search results
Showing 406 to 420 of 8901 results
All NICE products on infants and neonates. Includes any guidance, advice and quality standards.
All NICE products on carers. Includes any guidance and quality standards.
All NICE products on multiple sclerosis. Includes any guidance, advice and quality standards.
All NICE products on parkinson's disease, tremor and dystonia. Includes any guidance, advice and quality standards.
All NICE products on spasticity. Includes any guidance and advice.
All NICE products on transient loss of consciousness. Includes any guidance and quality standards.
All NICE products on care homes. Includes any guidance and quality standards.
All NICE products on oesophageal cancer. Includes any guidance and quality standards.
All NICE products on ear, nose and throat conditions. Includes any guidance, advice and quality standards.
All NICE products on upper gastrointestinal bleeding. Includes any guidance, advice and quality standards.
All NICE products on bites and stings. Includes any guidance and quality standards.
All NICE products on tuberculosis. Includes any guidance and quality standards.
All NICE products on influenza. Includes any guidance and quality standards.
All NICE products on feverish illness. Includes any guidance and quality standards.
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
View quality statements for QS18Show all sections
Sections for QS18
- Quality statements
- Quality statement 1: Discussion about risk-reducing surgery
- Quality statement 2 (placeholder): CA125 blood test – age-specific thresholds
- Quality statement 3: Panel germline genetic testing for non-mucinous high-grade epithelial ovarian cancer
- Quality statement 4: Tumour genetic testing for stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer
- Quality statement 5: Treatment of high-risk stage 1 or stage 2 to 4 ovarian cancer
- Update information
- About this quality standard